Methods: We analyzed treatment outcomes for 108 Belarusian MDR-TB patients receiving chemotherapy. Thirty-six patients (cases) also had MSCs collected, extracted, cultured, and reinfused (average time from chemotherapy start to infusion was 49 days) in optimal dose; another 36 patients (without MSC treatment) were ''study controls". We identified another control group: 36 patients from the Belarusian national surveillance database (surveillance controls) 1:1 matched to cases.
Results: Successful outcomes were observed in 81% of cases, 42% of surveillance controls, and 39% of study controls. After adjusting for age, odds of a successful outcome were 6.5 (95% confidence interval, 1.2-36.2, p = 0.032) times greater for cases than surveillance controls.
Adjusting for other potential confounders increased the effect estimate while maintaining statistical significance. Cases were less likely (p = 0.01) to be culture negative at 2 months than surveillance controls, indicating a poorer initial prognosis in cases before (or shortly after) infusion. Radiological improvement was more likely in cases than in study controls.
Conclusion: MSC treatment could vastly improve treatment outcomes for MDR-TB patients.
Our findings could revolutionize therapy options and have strong implications for future directions of MDR-TB therapy research
